Glaucoma Drug Therapy in Pregnancy: Literature Review and Teratology Information Service (TIS) Case Series

Author(s): Marcella Pellegrino*, Luisa D`Oria, Carmen De Luca, Giacomina Chiaradia, Angelo Licameli, Caterina Neri, Marta Nucci, Daniela Visconti, Alessandro Caruso, Marco De Santis

Journal Name: Current Drug Safety

Volume 13 , Issue 1 , 2018

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: There are many contradictions about pregnancy and fetal/neonatal outcomes after topical use of timolol alone or timolol in combination with other antiglaucoma medications.

Methods: Seventy-five pregnant women exposed to antiglaucoma medications were followed prospectively by phone interviews. 27 women used timolol as monotherapy, 48 women used timolol as a part of multidrug therapy. We selected a control group of 187 healthy pregnant women.

Results: Topical use of timolol alone or timolol in combination with other antiglaucoma medications does not influence pregnancy or fetal/neonatal outcomes.

Conclusion: Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded.

Keywords: Congenital anomalies, drugs, glaucoma, pregnancy, prenatal diagnosis, Teratology Information Service (TIS).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 27 March, 2018
Page: [3 - 11]
Pages: 9
DOI: 10.2174/1574886312666171030125804
Price: $65

Article Metrics

PDF: 84
HTML: 14
PRC: 1